Analyzing cancer through advanced genomic techniques
Official title: Immunogenomics platform for the analysis of cancer
Funded at Cleveland Clinic Lerner Com-Cwru · NIH-10977134 · Data updated 2026-11-12
This study is looking at how changes in genes can influence how well immunotherapy works for cancer patients, like those with melanoma or lung cancer, to help create more personalized treatment plans that could lead to better results.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cleveland Clinic Lerner Com-Cwru NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project start | September 13, 2024 |
| Project end | August 31, 2029 |
| Funding year | 2024 |
| Award (this year) | $212,567 |
| NIH project number | 1R50CA293821-01 |
| Project ID | NIH-10977134 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are cancer patients, particularly those with melanoma or non-small cell lung cancer, who are considering or currently receiving immunotherapy.
✕Less likely to help
Patients with early-stage cancers or those not receiving immunotherapy may not benefit from this research.
What this research studies
This research focuses on using advanced computational methods to analyze genetic data from cancer patients, particularly through Next Generation Sequencing (NGS). The goal is to enhance our understanding of how genetic alterations affect the efficacy of immunotherapy treatments in various cancers, including melanoma and lung cancer. By leveraging large datasets, the research aims to identify molecular drivers that can inform personalized treatment strategies for patients. The findings could lead to improved outcomes for individuals undergoing immunotherapy.
Why it matters
Potential benefit: If successful, this research could lead to more effective and personalized immunotherapy treatments for cancer patients.
How similar studies have gone: Previous research has shown success in using computational genomics to improve immunotherapy outcomes, indicating that this approach has the potential for significant advancements.
Where this research is happening
-
Cleveland Clinic Lerner Com-Cwru
Cleveland, United States Active
Researchers
- Principal investigator: Makarov, Vladimir — Cleveland Clinic Lerner Com-Cwru
- Study coordinator: Makarov, Vladimir
Related research
Other NIH-funded projects on the same topics.
-
Susceptibility-based MRI biomarkers for multiple sclerosis
A short-term study aims to test MRI biomarkers that could help diagnose and predict MS in patients, using advanced imaging techniques.
-
Population genomics in peripartum cardiomyopathy
A gene-focused study to understand why some women develop heart failure around and after pregnancy, with an emphasis on African ancestry.
-
Broad antiviral therapy by targeting a key enzyme in nucleotide synthesis
A plan to block a human enzyme that many viruses need, with the aim of creating a broad-spectrum antiviral treatment for infections like SARS-CoV-2, influenza, and HSV-1.
-
Cellular-level Vascular Oculomics for Monitoring Systemic Vascular Health
A multi-site project using eye imaging and AI to monitor blood vessel health in people, with devices and software developed across four clinical sites.
-
Cellular-level Eye Signals to Track Vascular Health
A multi-site project aims to create and test portable imaging devices and AI tools that can monitor blood vessel health through the eye.
-
Outcomes in cirrhosis from different causes and the role of HIV and simvastatin
This study looks at how cirrhosis from alcohol, HIV, and other causes affects patients and whether simvastatin can influence outcomes.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.